Search

Your search keyword '"Kang, Yoon-Koo"' showing total 1,453 results
Start Over Author "Kang, Yoon-Koo"

Refine your results

more »

more »

more »

more »

more »
1,453 results on '"Kang, Yoon-Koo"'

1. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.

Author

Wainberg, Zev, Kang, Yoon-Koo, Lee, Keun-Wook, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang, Li, Jin, Turk, Haci, Teixeira, Alexandra, Hitre, Erika, Udrea, Adrian, Cardellino, Giovanni, Sanchez, Raquel, Zahlten-Kümeli, Anita, Taylor, Kate, and Enzinger, Peter

Subjects
Bemarituzumab, FGFR2b, Gastric cancer, Targeted therapy, mFOLFOX6, Humans, Stomach Neoplasms, Fluorouracil, Receptor, Fibroblast Growth Factor, Type 2, Adenocarcinoma, Esophagogastric Junction, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Antibodies, Monoclonal, Humanized
Abstract

BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 + /3 + membranous staining by immunohistochemistry), HER-2-negative gastric or gastroesophageal junction cancer (GC). METHODS: Patients received bemarituzumab (15 mg/kg) or placebo once every 2 weeks with an additional bemarituzumab (7.5 mg/kg) or placebo dose on cycle 1 day 8. All patients received mFOLFOX6. The primary endpoint was investigator-assessed progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate, and safety. Efficacy was evaluated after a minimum follow-up of 24 months. RESULTS: In the bemarituzumab-mFOLFOX6 (N = 77) and placebo-mFOLFOX6 (N = 78) arms, respectively, 59.7% and 66.7% of patients were FGFR2b-positive in ≥ 10% of tumor cells. The median PFS (95% confidence interval [CI]) was 9.5 months (7.3-13.7) with bemarituzumab-mFOLFOX6 and 7.4 months (5.7-8.4) with placebo-mFOLFOX6 (hazard ratio [HR], 0.72; 95% CI 0.49-1.08); median OS (95% CI) was 19.2 (13.6-24.2) and 13.5 (9.3-15.9) months, respectively (HR 0.77; 95% CI 0.52-1.14). Observed efficacy in FGFR2b-positive GC in ≥ 10% of tumor cells was: PFS: HR 0.43 (95% CI 0.26-0.73); OS: HR 0.52 (95% CI 0.31-0.85). No new safety findings were reported. CONCLUSIONS: In FGFR2b-positive advanced GC, the combination of bemarituzumab-mFOLFOX6 led to numerically longer median PFS and OS compared with mFOLFOX6 alone. Efficacy was more pronounced with FGFR2b overexpression in ≥ 10% of tumor cells. Confirmatory phase 3 trials are ongoing (NCT05052801, NCT05111626). CLINICAL TRIAL REGISTRATION: NCT03694522.

Published
2024

3. Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial

Author

Boku, Narikazu, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Yamaguchi, Kensei, Kato, Ken, Kadowaki, Shigenori, Tsuji, Kunihiro, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Rha, Sun Young, Lee, Keun-Wook, Chung, Ik-Joo, Sym, Sun Jin, Chen, Li-Tzong, Chen, Jen-Shi, Bai, Li-Yuan, Nakada, Takashi, Hagihara, Shunsuke, Makino, Reina, Nishiyama, Eiji, and Kang, Yoon-Koo

Published
2024
Full Text
View/download PDF

7. Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial

Author

Kang, Yoon-Koo, Ryu, Min-Hee, Di Bartolomeo, Maria, Chau, Ian, Yoon, Harry, Kim, Jong Gwang, Lee, Keun-Wook, Oh, Sang Chul, Takashima, Atsuo, Kryzhanivska, Anna, Chao, Yee, Evesque, Ludovic, Schenker, Michael, McGinn, Arlo, Zhao, Yufan, Lee, Jennifer, Wyrwicz, Lucjan, and Boku, Narikazu

Published
2024
Full Text
View/download PDF

8. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Author

Heinrich, Michael C., Jones, Robin L., George, Suzanne, Gelderblom, Hans, Schöffski, Patrick, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Siontis, Brittany L., Goldstein, David, Boye, Kjetil, Sanchez, Cesar, Steeghs, Neeltje, Rutkowski, Piotr, Druta, Mihaela, Serrano, César, Somaiah, Neeta, Chi, Ping, Reichmann, William, Sprott, Kam, Achour, Haroun, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Blay, Jean-Yves, and Bauer, Sebastian

Published
2024
Full Text
View/download PDF

11. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Author

Kang, Yoon-Koo, Terashima, Masanori, Kim, Young-Woo, Boku, Narikazu, Chung, Hyun Cheol, Chen, Jen-Shi, Ji, Jiafu, Yeh, Ta-Sen, Chen, Li-Tzong, Ryu, Min-Hee, Kim, Jong Gwang, Omori, Takeshi, Rha, Sun Young, Kim, Tae Yong, Ryu, Keun Won, Sakuramoto, Shinichi, Nishida, Yasunori, Fukushima, Norimasa, Yamada, Takanobu, Bai, Li-Yuan, Hirashima, Yoshinori, Hagihara, Shunsuke, Nakada, Takashi, and Sasako, Mitsuru

Published
2024
Full Text
View/download PDF

12. Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach

Author

Kong, Seong-Ho, Kurokawa, Yukinori, Yook, Jeong-Hwan, Cho, Haruhiko, Kwon, Oh-Kyoung, Masuzawa, Toru, Lee, Kyung Hee, Matsumoto, Sohei, Park, Young Soo, Honda, Hiroshi, Ryu, Seung-Wan, Ishikawa, Takashi, Kang, Hye Jin, Nabeshima, Kazuhito, Im, Seock-Ah, Shimokawa, Toshio, Kang, Yoon-Koo, Hirota, Seiichi, Yang, Han-Kwang, and Nishida, Toshirou

Published
2023
Full Text
View/download PDF

15. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Azevedo, Sergio, Braghiroli, Maria Ignez, Girotto, Gustavo, Bragagnoli, Arinilda, Branco, Ricardo, Faccio, Adilson, Moretto, Andrea, Skare, Nils, Dutra, Jamille, Viola, Luciana, Vianna, Karina, Meton, Fernando, Sette, Claudia, Faulhaber, Amanda, Tam, Vincent C., Couture, Felix, Biagi, Jim, Castel, Helene, Mulder, Karen, Ko, Yoo-Joung, Zbuk, Kevin, Welch, Stephen, Beaudoin, Annie, Heurgué, Alexandra, Assenat, Eric, Archambeaud, Isabelle, Tougeron, David, Peron, Jean-Marie, Gilabert, Marine, Bronowicki, Jean-Pierre, Cattan, Stephane, Blanc, Jean-Frederic, Bouattour, Mohamed, Phelip, Jean-Marc, Boige, Valerie, Michel, Pierre, Frin, Anne-Claire, De Toni, Enrico N., Berres, Marie-Luise, Vogel, Arndt, Berg, Thomas, Ettrich, Thomas, Waldschmidt, Dirk, Wedemeyer, Hans Heinrich, Worns, Marcus-Alexander, Bitzer, Michael, Weiss, Karl-Heinz, Lau, George, Chan, Stephen L., Yau, Thomas, Tai, Yin Ping, Lee, Ann Shing, Thungappa, Satheesh Chiradoni, N, Lokesh K., Sureshchand Ostwal, Vikas, Ashok, Kattimani Kiran, Mittal, Sushant, Goyal, Hari, Srinivasan, Sankar, Biswas, Ghanashyam, Mohan, Mallavarapu, Limaye, Sewanti, Asarawala, Nirav, Rimassa, Lorenza, Falcone, Alfredo, Gianni, Luca, Gasbarrini, Antonio, Daniele, Bruno, Avallone, Antonio, Paolo Frassineti, Giovanni Luca, Roila, Fausto, Kudo, Masatoshi, Kawaoka, Tomokazu, Morimoto, Manabu, Takikawa, Yasuhiro, Kato, Naoya, Yamashita, Tatsuya, Osaki, Yukio, Motomura, Kenta, Tateishi, Ryosuke, Ohkawa, Kazuyoshi, Wada, Yoshiyuki, Onishi, Hideki, Sasahira, Naoki, Inaba, Yoshitaka, Kurosaki, Masayuki, Tsuji, Kunihiko, Takei, Yoshiyuki, Aramaki, Takeshi, Hagihara, Atsushi, Furuse, Junji, Kioka, Kiyohide, Koga, Hironori, Sasaki, Yutaka, Numata, Kazushi, Tada, Toshifumi, Kawaguchi, Yasunori, Nadano, Seijin, Vasilyev, Alexander, Breder, Valery, Lipatov, Oleg, Dvorkin, Mikhail, Zarubenkov, Oleg, Kutukova, Svetlana, Ponomarev, Roman, Shostka, Kirill, Alyasova, Anna, Topuzov, Eldar, Severtsev, Alexey, Petrov, Yuryi, Erygin, Dmitriy, Berdov, Boris, Kang, Yoon-Koo, Tak, Won-Young, Park, Joong-Won, Lim, Ho Yeong, Heo, Jeong, Kim, Jee Hyun, Kim, Tae-You, Choi, Hye Jin, Varela, María, Reig Monzon, María Elisa, Sangro, Bruno, Martin, Carlos Gómez, Ponce, Carmen Guillén, López, Carlos, Cheng, Ann-Lii, Chao, Yee, Feng, Yin-Hsun, Jeng, Long-Bin, Hung, Chao-Hung, Hou, Ming-Mo, Wang Tsang-En Wang, Jing-Houng, Yen, Chia-Jui, Sukeepaisarnjaroen, Wattana, Sunpaweravong, Patrapim, Charoentum, Chaiyut, Tanasanvimon, Suebpong, Sirachainan, Ekaphop, Ungtrakul, Teerapat, Prasongsook, Naiyarat, Maneenil, Kunlatida, Jitpewngarm, Wittawat, Ostapenko, Yurii, Skoryi, Denys, Bondarenko, Igor, Shparyk, Yaroslav, Trukhin, Dmytro, Hotko, Yevhen, Ursol, Grygorii, Kryzhanivska, Anna, Abou-Alfa, Ghassan K., Mody, Kabir, Dayyani, Farshid, Al-Rajabi, Raed, Yarchoan, Mark, Gandhi, Sunil, Crysler, Oxana, He, Aiwu Ruth, Reeves, James, Bahary, Nathan, Mahipal, Amit, Kelley, Robin Kate, Dasgupta, Anirudha, Rowe, Julie, Thota, Ramya, Beg, Muhammad, Morse, Michael, Choi, Sung-hee, Crocenzi, Todd, Somer, Bradley, Abrams, Thomas, Denlinger, Crystal, Zhang, Yue, Sharma, Nisha, Dao, Tu V., Thinh, Nguyen Tien, Tuyet Phuong, Le Thi, Sangro, B., Chan, S.L., Kelley, R.K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E.N., Furuse, J., Kang, Y.K., Galle, P.R., Rimassa, L., Heurgué, A., Tam, V.C., Van Dao, T., Thungappa, S.C., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Paskow, M.J., Gupta, C., Kurland, J.F., Negro, A., and Abou-Alfa, G.K.

Published
2024
Full Text
View/download PDF

16. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

Author

Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John, and Goldstein, David

Published
2023
Full Text
View/download PDF

17. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Lau, George, Abou-Alfa, Ghassan K., Cheng, Ann-Lii, Sukeepaisarnjaroen, Wattana, Van Dao, Tu, Kang, Yoon Koo, Thungappa, Satheesh Chiradoni, Kudo, Masatoshi, Sangro, Bruno, Kelley, Robin Kate, Furuse, Junji, Park, Joong-Won, Sunpaweravong, Patrapim, Fasolo, Angelica, Yau, Thomas, Kawaoka, Tomokazu, Azevedo, Sergio, Reig, Maria, Assenat, Eric, Yarchoan, Mark, He, Aiwu Ruth, Makowsky, Mallory, Gupta, Charu, Negro, Alejandra, and Chan, Stephen L.

Published
2024
Full Text
View/download PDF

18. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Author

Kelley, Robin Kate, Sangro, Bruno, Harris, William, Ikeda, Masafumi, Okusaka, Takuji, Kang, Yoon-Koo, Qin, Shukui, Tai, David W-M, Lim, Ho Yeong, Yau, Thomas, Yong, Wei-Peng, Cheng, Ann-Lii, Gasbarrini, Antonio, Damian, Silvia, Bruix, Jordi, Borad, Mitesh, Bendell, Johanna, Kim, Tae-You, Standifer, Nathan, He, Philip, Makowsky, Mallory, Negro, Alejandra, Kudo, Masatoshi, and Abou-Alfa, Ghassan K

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, HIV/AIDS, Orphan Drug, Rare Diseases, Cancer, Biotechnology, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, Liver Cancer, Patient Safety, Liver Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThis phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).Patients and methodsPatients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles.ResultsA total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively.ConclusionAll regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.

Published
2021

20. Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Author

Gelderblom, Hans, Jones, Robin L., Blay, Jean-Yves, George, Suzanne, von Mehren, Margaret, Zalcberg, John R., Kang, Yoon-Koo, Razak, Albiruni Abdul, Trent, Jonathan, Attia, Steven, Le Cesne, Axel, Siontis, Brittany L., Goldstein, David, Boye, Kjetil, Sanchez, Cesar, Steeghs, Neeltje, Rutkowski, Piotr, Druta, Mihaela, Serrano, César, Somaiah, Neeta, Chi, Ping, Harrow, Brooke, Becker, Claus, Reichmann, William, Sherman, Matthew L., Ruiz-Soto, Rodrigo, Heinrich, Michael C., and Bauer, Sebastian

Published
2023
Full Text
View/download PDF

21. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma

Author

Catenacci, Daniel V.T., Kang, Yoon-Koo, Uronis, Hope E., Lee, Keun-Wook, Ng, Matthew C.H., Enzinger, Peter C., Park, Se Hoon, Gold, Philip J., Lacy, Jill, Hochster, Howard S., Oh, Sang Cheul, Kim, Yeul Hong, Marrone, Kristen A., Kelly, Ronan J., Juergens, Rosalyn A., Kim, Jong Gwang, Alcindor, Thierry, Sym, Sun Jin, Song, Eun-Kee, Chee, Cheng Ean, Chao, Yee, Kim, Sunnie, Oh, Do-Youn, Yen, Jennifer, Odegaard, Justin I., Lagow, Errin, Li, Daner, Sun, Jichao, Kaminker, Patrick, Moore, Paul A., Rosales, Minori Koshiji, and Park, Haeseong

Subjects
Merck KGaA, MacroGenics Inc., Bayer AG, AstraZeneca PLC, Medical research, Medicine, Experimental, Immunohistochemistry, Tumors -- Patient outcomes, DNA, Adenocarcinoma -- Patient outcomes, Pharmaceutical industry, Health
Abstract

PURPOSE. To assess the ability of circulating tumor DNA (ctDNA)-based testing to identify patients with HER2 (encoded by ERBB2)-positive gastric/gastroesophageal adenocarcinoma (GEA) who progressed on or after trastuzumab-containing treatments were treated with combination therapy of anti-HER2 and anti-PD-1 agents. METHODS. ctDNA analysis was performed retrospectively using plasma samples collected at study entry from 86 patients participating in the phase 1/2 CP-MGAH22-05 study (NCT02689284). RESULTS. Objective response rate (ORR) was significantly higher in evaluable ERBB2 amplification-positive vs negative patients based on ctDNA analysis at study entry (37% vs 6%, respectively; P = .00094). ORR was 23% across all patients who were evaluable for response. ERBB2 amplification was detected at study entry in 57% of patients (all HER2 positive at diagnosis), and detection was higher (88%) when HER2 status was determined by immunohistochemistry fewer than 6 months before study entry. ctDNA was detected in 98% (84/86) of patients tested at study entry. Codetected ERBB2-activating mutations were not associated with response. CONCLUSIONS. Current ERBB2 status may be more effective than archival status at predicting clinical benefit from margetuximab plus pembrolizumab therapy. ctDNA testing for ERBB2 status prior to treatment will spare patients from repeat tissue biopsies, which may be reserved for reflex testing when ctDNA is not detected. KEYWORDS. gastric/gastroesophageal adenocarcinoma; HER2; ctDNA; and margetuximab plus pembrolizumab, BACKGROUND The human epidermal growth factor receptor 2 (HER2) protein is a receptor tyrosine-protein kinase, encoded by erythroblastic oncogene B2 (ERBB2), normally involved in the proliferation and division of cells. [...]

Published
2023

22. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study

Author

Kim, Hyung-Don, Lee, Jong Seok, Park, Young Soo, Yook, Jeong Hwan, Noh, Sung Hoon, Park, Young-Kyu, Kim, Young-Woo, Oh, Sang Cheul, Kim, Jong Gwang, Ryu, Min-Hee, Cheong, Jae-Ho, Kim, HyunKi, Lim, Joon Seok, Lee, Jae-Hyuk, Heo, Suk Hee, Kim, Jin Young, Heo, Mi Hwa, Park, Young Iee, Kim, In-Ho, and Kang, Yoon-Koo

Published
2022
Full Text
View/download PDF

23. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Author

Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Shah, Manish A, Van Cutsem, Eric, Xu, Rui-Hua, Aprile, Giuseppe, Xu, Jianming, Chao, Joseph, Pazo-Cid, Roberto, Kang, Yoon-Koo, Yang, Jianning, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, Park, Jung Wook, Oh, Mok, and Ajani, Jaffer A

Published
2023
Full Text
View/download PDF

26. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Author

Meric-Bernstam, Funda, Beeram, Muralidhar, Hamilton, Erika, Oh, Do-Youn, Hanna, Diana L, Kang, Yoon-Koo, Elimova, Elena, Chaves, Jorge, Goodwin, Rachel, Lee, Jeeyun, Nabell, Lisle, Rha, Sun Young, Mayordomo, Jose, El-Khoueiry, Anthony, Pant, Shubham, Raghav, Kanwal, Kim, Jin Won, Patnaik, Amita, Gray, Todd, Davies, Rupert, Ozog, Mark A, Woolery, Joseph, and Lee, Keun-Wook

Published
2022
Full Text
View/download PDF

27. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Author

Wainberg, Zev A, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Borg, Christophe, Hitre, Erika, Udrea, Adrian A, Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Collins, Helen, Mitra, Siddhartha, Yang, Yingsi, Catenacci, Daniel V T, and Lee, Keun-Wook

Published
2022
Full Text
View/download PDF

28. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Author

Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V, Muro, Kei, Fuchs, Charles S, Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I, Borg, Christophe, Doi, Toshihiko, Yoon, Harry H, Savage, Mary J, Wang, Jiangdian, Dalal, Rita P, Shah, Sukrut, Wainberg, Zev A, and Chung, Hyun Cheol

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Rare Diseases, Clinical Research, Digestive Diseases, Patient Safety, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Capecitabine, Carcinoma, Signet Ring Cell, Cisplatin, Cohort Studies, Esophageal Neoplasms, Esophagogastric Junction, Female, Fluorouracil, Follow-Up Studies, Humans, Japan, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Stomach Neoplasms, Survival Rate, Young Adult, Pembrolizumab, 5-Fluorouracil, Gastric cancer, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BACKGROUND:The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented. METHODS:Patients ≥ 18 years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Cohort 3 (monotherapy) had programmed death receptor 1 combined positive score ≥ 1. Cohort 2 (combination therapy) received pembrolizumab 200 mg on day 1, cisplatin 80 mg/m2 on day 1 (up to 6 cycles), and 5-fluorouracil 800 mg/m2 on days 1-5 of each 3-week cycle (or capecitabine 1000 mg/m2 twice daily in Japan). Primary end points were safety (combination therapy) and objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by central review, and safety (monotherapy). RESULTS:In the combination therapy and monotherapy cohorts, 25 and 31 patients were enrolled; median follow-up was 13.8 months (range 1.8-24.1) and 17.5 months (range 1.7-20.7), respectively. In the combination therapy cohort, grade 3/4 treatment-related adverse events occurred in 19 patients (76.0%); none were fatal. In the monotherapy cohort, grade 3-5 treatment-related adverse events occurred in seven patients (22.6%); one death was attributed to a treatment-related adverse event (pneumonitis). The objective response rate was 60.0% [95% confidence interval (CI), 38.7-78.9] (combination therapy) and 25.8% (95% CI 11.9-44.6) (monotherapy). CONCLUSIONS:Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma. CLINICAL TRIAL:ClinicalTrials.gov NCT02335411.

Published
2019

31. Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study

Author

Kang, Yoon-Koo, Morita, Satoshi, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Sameshima, Hiroki, Chen, Li-Tzong, and Boku, Narikazu

Published
2022
Full Text
View/download PDF

33. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Author

Chan, Stephen L., Schuler, Martin, Kang, Yoon-Koo, Yen, Chia-Jui, Edeline, Julien, Choo, Su Pin, Lin, Chia-Chi, Okusaka, Takuji, Weiss, Karl-Heinz, Macarulla, Teresa, Cattan, Stéphane, Blanc, Jean-Frederic, Lee, Kyung-Hun, Maur, Michela, Pant, Shubham, Kudo, Masatoshi, Assenat, Eric, Zhu, Andrew X., Yau, Thomas, Lim, Ho Yeong, Bruix, Jordi, Geier, Andreas, Guillén-Ponce, Carmen, Fasolo, Angelica, Finn, Richard S., Fan, Jia, Vogel, Arndt, Qin, Shukui, Riester, Markus, Katsanou, Vasiliki, Chaudhari, Monica, Kakizume, Tomoyuki, Gu, Yi, Porta, Diana Graus, Myers, Andrea, and Delord, Jean-Pierre

Published
2022
Full Text
View/download PDF

34. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Author

Kang, Yoon-Koo, Chen, Li-Tzong, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Chung, Hyun Cheol, Lee, Keun-Wook, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Chung, Ik-Joo, Yamaguchi, Kensei, Kato, Ken, Sym, Sun Jin, Kadowaki, Shigenori, Tsuji, Kunihiro, Chen, Jen-Shi, Bai, Li-Yuan, Oh, Sung-Yong, Choda, Yasuhiro, Yasui, Hisateru, Takeuchi, Kentaro, Hirashima, Yoshinori, Hagihara, Shunsuke, and Boku, Narikazu

Published
2022
Full Text
View/download PDF

35. Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.

Author

Kang, Yoon-Koo, Kim, Hyung-Don, Yook, Jeong Hwan, Park, Young-Kyu, Lee, Jong Seok, Kim, Young-Woo, Kim, Jin Young, Ryu, Min-Hee, Rha, Sun Young, Chung, Ik Joo, Kim, In-Ho, Oh, Sang Cheul, Park, Young Soo, Cheong, Jae-Ho, Jeong, Oh, Heo, Mi Hwa, Kim, Hark Kyun, Park, ChoHyun, Yoo, Chang Hak, and Kang, Seok Yun

Published
2024
Full Text
View/download PDF

36. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Author

Sangro, B., primary, Chan, S.L., additional, Kelley, R.K., additional, Lau, G., additional, Kudo, M., additional, Sukeepaisarnjaroen, W., additional, Yarchoan, M., additional, De Toni, E.N., additional, Furuse, J., additional, Kang, Y.K., additional, Galle, P.R., additional, Rimassa, L., additional, Heurgué, A., additional, Tam, V.C., additional, Van Dao, T., additional, Thungappa, S.C., additional, Breder, V., additional, Ostapenko, Y., additional, Reig, M., additional, Makowsky, M., additional, Paskow, M.J., additional, Gupta, C., additional, Kurland, J.F., additional, Negro, A., additional, Abou-Alfa, G.K., additional, Azevedo, Sergio, additional, Braghiroli, Maria Ignez, additional, Girotto, Gustavo, additional, Bragagnoli, Arinilda, additional, Branco, Ricardo, additional, Faccio, Adilson, additional, Moretto, Andrea, additional, Skare, Nils, additional, Dutra, Jamille, additional, Viola, Luciana, additional, Vianna, Karina, additional, Meton, Fernando, additional, Sette, Claudia, additional, Faulhaber, Amanda, additional, Tam, Vincent C., additional, Couture, Felix, additional, Biagi, Jim, additional, Castel, Helene, additional, Mulder, Karen, additional, Ko, Yoo-Joung, additional, Zbuk, Kevin, additional, Welch, Stephen, additional, Beaudoin, Annie, additional, Heurgué, Alexandra, additional, Assenat, Eric, additional, Archambeaud, Isabelle, additional, Tougeron, David, additional, Peron, Jean-Marie, additional, Gilabert, Marine, additional, Bronowicki, Jean-Pierre, additional, Cattan, Stephane, additional, Blanc, Jean-Frederic, additional, Bouattour, Mohamed, additional, Phelip, Jean-Marc, additional, Boige, Valerie, additional, Michel, Pierre, additional, Frin, Anne-Claire, additional, Enrico N De Toni, Germany, additional, Berres, Marie-Luise, additional, Vogel, Arndt, additional, Berg, Thomas, additional, Ettrich, Thomas, additional, Waldschmidt, Dirk, additional, Wedemeyer, Hans Heinrich, additional, Worns, Marcus-Alexander, additional, Bitzer, Michael, additional, Weiss, Karl-Heinz, additional, Lau, George, additional, Chan, Stephen L., additional, Yau, Thomas, additional, Tai, Yin Ping, additional, Lee, Ann Shing, additional, Thungappa, Satheesh Chiradoni, additional, N, Lokesh K., additional, Ostwal, Vikas Sureshchand, additional, Ashok, Kattimani Kiran, additional, Mittal, Sushant, additional, Goyal, Hari, additional, Srinivasan, Sankar, additional, Biswas, Ghanashyam, additional, Mohan, Mallavarapu, additional, Limaye, Sewanti, additional, Asarawala, Nirav, additional, Rimassa, Lorenza, additional, Falcone, Alfredo, additional, Gianni, Luca, additional, Gasbarrini, Antonio, additional, Daniele, Bruno, additional, Avallone, Antonio, additional, Paolo Frassineti, Giovanni Luca, additional, Roila, Fausto, additional, Kudo, Masatoshi, additional, Kawaoka, Tomokazu, additional, Morimoto, Manabu, additional, Takikawa, Yasuhiro, additional, Kato, Naoya, additional, Yamashita, Tatsuya, additional, Osaki, Yukio, additional, Motomura, Kenta, additional, Tateishi, Ryosuke, additional, Ohkawa, Kazuyoshi, additional, Wada, Yoshiyuki, additional, Onishi, Hideki, additional, Sasahira, Naoki, additional, Inaba, Yoshitaka, additional, Kurosaki, Masayuki, additional, Tsuji, Kunihiko, additional, Takei, Yoshiyuki, additional, Aramaki, Takeshi, additional, Hagihara, Atsushi, additional, Furuse, Junji, additional, Kioka, Kiyohide, additional, Koga, Hironori, additional, Sasaki, Yutaka, additional, Numata, Kazushi, additional, Tada, Toshifumi, additional, Kawaguchi, Yasunori, additional, Nadano, Seijin, additional, Alexander Vasilyev, Russian Federation, additional, Breder, Valery, additional, Lipatov, Oleg, additional, Dvorkin, Mikhail, additional, Zarubenkov, Oleg, additional, Kutukova, Svetlana, additional, Ponomarev, Roman, additional, Shostka, Kirill, additional, Alyasova, Anna, additional, Topuzov, Eldar, additional, Severtsev, Alexey, additional, Petrov, Yuryi, additional, Erygin, Dmitriy, additional, Berdov, Boris, additional, Kang, Yoon-Koo, additional, Tak, Won-Young, additional, Park, Joong-Won, additional, Lim, Ho Yeong, additional, Heo, Jeong, additional, Kim, Jee Hyun, additional, Kim, Tae-You, additional, Choi, Hye Jin, additional, Varela, María, additional, Reig Monzon, María Elisa, additional, Sangro, Bruno, additional, Martin, Carlos Gómez, additional, Ponce, Carmen Guillén, additional, López, Carlos, additional, Cheng, Ann-Lii, additional, Chao, Yee, additional, Feng, Yin-Hsun, additional, Jeng, Long-Bin, additional, Hung, Chao-Hung, additional, Hou, Ming-Mo, additional, Wang Tsang-En Wang, Jing-Houng, additional, Yen, Chia-Jui, additional, Sukeepaisarnjaroen, Wattana, additional, Sunpaweravong, Patrapim, additional, Charoentum, Chaiyut, additional, Tanasanvimon, Suebpong, additional, Sirachainan, Ekaphop, additional, Ungtrakul, Teerapat, additional, Prasongsook, Naiyarat, additional, Maneenil, Kunlatida, additional, Jitpewngarm, Wittawat, additional, Ostapenko, Yurii, additional, Skoryi, Denys, additional, Bondarenko, Igor, additional, Shparyk, Yaroslav, additional, Trukhin, Dmytro, additional, Hotko, Yevhen, additional, Ursol, Grygorii, additional, Kryzhanivska, Anna, additional, Abou-Alfa, Ghassan K., additional, Mody, Kabir, additional, Dayyani, Farshid, additional, Al-Rajabi, Raed, additional, Yarchoan, Mark, additional, Gandhi, Sunil, additional, Crysler, Oxana, additional, He, Aiwu Ruth, additional, Reeves, James, additional, Bahary, Nathan, additional, Mahipal, Amit, additional, Kelley, Robin Kate, additional, Dasgupta, Anirudha, additional, Rowe, Julie, additional, Thota, Ramya, additional, Beg, Muhammad, additional, Morse, Michael, additional, Choi, Sung-hee, additional, Crocenzi, Todd, additional, Somer, Bradley, additional, Abrams, Thomas, additional, Denlinger, Crystal, additional, Zhang, Yue, additional, Sharma, Nisha, additional, Dao, Tu V., additional, Thinh, Nguyen Tien, additional, and Tuyet Phuong, Le Thi, additional

Published
2024
Full Text
View/download PDF

37. Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).

Author

Li, Daneng, primary, Rau, Kun-Ming, additional, Yu, Ming-Lung, additional, Chon, Hong Jae, additional, Lai, Hsueh-Chou, additional, Pelster, Meredith, additional, Roberts, Stuart K., additional, Crysler, Oxana V., additional, Vaccaro, Gina M., additional, Womack, Mark Sanders, additional, Kim, Ju Won, additional, Yang, Jin-Mo, additional, Kim, Hyung-Don, additional, Hill, Jonathan, additional, REICHERT, VIENNA Lynn, additional, Masia, Ricard, additional, Harshman, Lauren C, additional, Hsu, Chih-Hung, additional, and Kang, Yoon-Koo, additional

Published
2024
Full Text
View/download PDF

38. Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors

Author

Kang, Yoon-Koo, primary, Ryu, Min-Hee, additional, Hong, Yong Sang, additional, Choi, Chang-Min, additional, Kim, Tae Won, additional, Ryoo, Baek-Yeol, additional, Kim, Jeong Eun, additional, Weis, John R., additional, Kingsford, Rachel, additional, Park, Cheol Hee, additional, Jang, Seong, additional, McGinn, Arlo, additional, Werner, Theresa L., additional, and Sharma, Sunil, additional

Published
2024
Full Text
View/download PDF

39. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

Author

Boku, Narikazu, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Nishiyama, Taihei, Chen, Li-Tzong, and Kang, Yoon-Koo

Published
2021
Full Text
View/download PDF

40. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2

Author

Kudo, Masatoshi, Galle, Peter R., Brandi, Giovanni, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S., Llovet, Josep M., Assenat, Eric, Merle, Philippe, Chan, Stephen L., Palmer, Daniel H., Ikeda, Masafumi, Yamashita, Tatsuya, Vogel, Arndt, Huang, Yi-Hsiang, Abada, Paolo B., Yoshikawa, Reigetsu, Shinozaki, Kenta, Wang, Chunxiao, Widau, Ryan C., and Zhu, Andrew X.

Published
2021
Full Text
View/download PDF

41. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

Author

Zhu, Andrew X., Finn, Richard S., Kang, Yoon-Koo, Yen, Chia-Jui, Galle, Peter R., Llovet, Josep M., Assenat, Eric, Brandi, Giovanni, Motomura, Kenta, Ohno, Izumi, Daniele, Bruno, Vogel, Arndt, Yamashita, Tatsuya, Hsu, Chih-Hung, Gerken, Guido, Bilbruck, John, Hsu, Yanzhi, Liang, Kun, Widau, Ryan C., Wang, Chunxiao, Abada, Paolo, and Kudo, Masatoshi

Published
2021
Full Text
View/download PDF

43. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Author

Catenacci, Daniel V T, Kang, Yoon-Koo, Park, Haeseong, Uronis, Hope E, Lee, Keun-Wook, Ng, Matthew C H, Enzinger, Peter C, Park, Se Hoon, Gold, Philip J, Lacy, Jill, Hochster, Howard S, Oh, Sang Cheul, Kim, Yeul Hong, Marrone, Kristen A, Kelly, Ronan J, Juergens, Rosalyn A, Kim, Jong Gwang, Bendell, Johanna C, Alcindor, Thierry, Sym, Sun Jin, Song, Eun-Kee, Chee, Cheng Ean, Chao, Yee, Kim, Sunnie, Lockhart, A Craig, Knutson, Keith L, Yen, Jennifer, Franovic, Aleksandra, Nordstrom, Jeffrey L, Li, Daner, Wigginton, Jon, Davidson-Moncada, Jan K, Rosales, Minori Koshiji, and Bang, Yung-Jue

Published
2020
Full Text
View/download PDF

44. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial

Author

Kang, Yoon-Koo, Chin, Keisho, Chung, Hyun Cheol, Kadowaki, Shigenori, Oh, Sang Cheul, Nakayama, Norisuke, Lee, Keun-Wook, Hara, Hiroki, Chung, Ik-Joo, Tsuda, Masahiro, Park, Se Hoon, Hosaka, Hisashi, Hironaka, Shuichi, Miyata, Yoshinori, Ryu, Min-Hee, Baba, Hideo, Hyodo, Ichinosuke, Bang, Yung-Jue, and Boku, Narikazu

Published
2020
Full Text
View/download PDF

45. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Author

Heinrich, Michael C, Jones, Robin L, von Mehren, Margaret, Schöffski, Patrick, Serrano, César, Kang, Yoon-Koo, Cassier, Philippe A, Mir, Olivier, Eskens, Ferry, Tap, William D, Rutkowski, Piotr, Chawla, Sant P, Trent, Jonathan, Tugnait, Meera, Evans, Erica K, Lauz, Tamieka, Zhou, Teresa, Roche, Maria, Wolf, Beni B, Bauer, Sebastian, and George, Suzanne

Published
2020
Full Text
View/download PDF

46. PP213 Three-year follow-up of the ATTRACTION-4 Korean subgroup analysis: First-line (1L) nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated, advanced, or recurrent gastric/gastro-esophageal junction (G/GEJ) cancer

Author

Ryu, Min-Hee, primary, Kang, Yoon-Koo, additional, Oh, Do-Youn, additional, Oh, Sang Cheul, additional, Rha, Sun Young, additional, Lee, Keun-Wook, additional, Chung, Ik Joo, additional, Oh, Sung Yong, additional, Sym, Sun Jin, additional, Kang, Won Ki, additional, Kim, Jong Gwang, additional, Shim, Byoung Yong, additional, Kim, In-Ho, additional, Kim, Jin Young, additional, Song, Eun-Kee, additional, Lee, Hyo-Jin, additional, Kang, Seok Yun, additional, Koo, Dong-Hoe, additional, and Oh, So Yeon, additional

Published
2023
Full Text
View/download PDF

47. Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy

Author

Kim, Eo Jin, primary, Chae, Heejung, additional, Park, Young-Soo, additional, Ryu, Min-Hee, additional, Kim, Hyung-Don, additional, Shin, Junyoung, additional, Park, Yang Soon, additional, Moon, Mee Sun, additional, and Kang, Yoon-Koo, additional

Published
2023
Full Text
View/download PDF

48. 716 Phase 2 study of the HER2-targeting TLR7/8 immune stimulating antibody conjugate (ISAC) BDC-1001 monotherapy +/- nivolumab in patients with HER2+ colorectal, endometrial, or gastroesophageal cancer

Author

Dumbrava, Ecaterina, primary, Mestres, Joan Albanell, additional, Ascierto, Paolo Antonio, additional, Blay, Jean-Yves, additional, Champiat, Stéphane, additional, Salgado, Alfonso Cortes, additional, Deleuze, Antoine, additional, GilMartin, Marta, additional, Heeke, Arielle, additional, Italiano, Antoine, additional, Kang, Yoon-Koo, additional, Lee, Jeeyun, additional, Lee, Keun-Wook, additional, Losurdo, Agnese, additional, Magni, Michele, additional, Moore, Kathleen, additional, Benzaquen, Ana Oaknin, additional, Zabalza, Ignacio Ortego, additional, Park, Haeseong, additional, Rodriguez, Luis Paz-Ares, additional, Pegram, Mark D, additional, Ponz-Sarvise, Mariano, additional, Rasco, Drew, additional, Sharma, Manish, additional, Shergill, Ardaman, additional, Spano, Jean-Philippe, additional, Spira, Alexander I, additional, Vicier, Cecile, additional, Victoria, Ivan, additional, Weinberg, Benjamin, additional, Tapia, Coya, additional, Ptacek, Jason, additional, Alonso, Michael N, additional, Xu, Lu, additional, Yin, Ming, additional, Perez, Edith A, additional, and Li, Bob T, additional

Published
2023
Full Text
View/download PDF

50. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

Author

Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, and Beg, Muhammad S.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results